NCT04871724已完成1 期
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- AUC of EDP-938 with and without coadministration with fluconazole
研究概览
简要总结
A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Inclusion Criteria:
- •An informed consent document signed and dated by the subject.
- •Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.
- •Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg
- •Female subjects of childbearing potential must agree to use two effective methods of contraception from the date of Screening until 90 days after the last dose of EDP 938.
排除标准
- •Clinically relevant evidence or history of illness or disease
- •Pregnant or nursing females.
- •History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
- •A positive urine drug screen at Screening or Day -
- •Current tobacco smokers or use of tobacco within 3 months prior to Screening.
- •Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
- •History of regular alcohol consumption.
- •Participation in a clinical trial within 30 days prior to the first dose of study drug.
- •Clinically significant history of drug sensitivity or allergy to fluconazole or other azole antifungals
研究组 & 干预措施
EDP-938 and Fluconazole interaction
Experimental
干预措施: EDP-938 (Drug)
EDP-938 and Fluconazole interaction
Experimental
干预措施: Fluconazole (Drug)
结局指标
主要结局
AUC of EDP-938 with and without coadministration with fluconazole
时间窗: Up to 19 days
Cmax of EDP-938 with and without coadministration with fluconazole
时间窗: Up to 19 days
次要结局
- Safety measured by adverse events(Up to 25 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy SubjectsTumorNCT05147727Jiangsu HengRui Medicine Co., Ltd.22
已完成
1 期
A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult ParticipantsHealthyNCT03135106Janssen Research & Development, LLC54
已完成
1 期
Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy SubjectsHealthy ParticipantsNCT02809768Eisai Inc.48
已完成
1 期
Pharmacokinetic Drug Interaction Study in Healthy Male SubjectsHealthy Male VolunteersNCT01426906LG Life Sciences24
已完成
1 期
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsHealthy VolunteersNCT04702464Celgene29